Orlando, FL – Clinerion and ASUS Life signed a strategic alliance today at the HIMSS 17 conference in Orlando, Florida. Clinerion and ASUS Life, together with the Show Chwan Healthcare System, will deliver innovative services for the efficient running of clinical trials, clinical patient recruitment, market access and real-world evidence in Taiwan.
ASUS Life is a unique joint venture which combines the power and reliability of ASUS’ information technology with the clinical research services of the Show Chwan Healthcare System, in Taiwan.
The new alliance between Clinerion and ASUS Life helps shorten the time it takes to bring a new drug to market, benefitting patients who get earlier access to new medicines.
With this collaboration, researchers at hospitals, pharmaceutical companies and contract research organizations gain real-time, EHR-based insight on the Taiwanese patient population. Eligible patients can subsequently be recruited by trial staff at Show Chwan’s 8 hospital sites. The collaboration will also enable the matching of patients with medications for rare and orphan diseases and the generation of data for real-world evidence analyses.
“We provide services that meet international standards in order to bring the best possible medical care to more people. We are therefore very pleased for Show Chwan’s patients to have more opportunities to gain earlier access to next generation medication via clinical trials and market access activities. Our patients with rare diseases will benefit from being matched with the latest medications coming onto the market,” says Prof. Min-Ho Huang, President of Show Chwan Healthcare System.
“Taiwan has tremendous potential for growth in the industry and we are delighted to host Clinerion’s PRS platform with ASUS technology and services and boost the number, quality and efficiency of clinical trials. We are excited about moving forward as strategic allies and promoting the advancement of clinical trial efficiency,” says Peter Wu, CEO of ASUS Life.
“The arrival of ASUS Life and Show Chwan on the PRS platform is another significant milestone in Clinerion’s expansion. Having already established our presence in Europe, Turkey, and the Americas, we are thrilled to enter the Asian Pacific region, and to welcome ASUS Life and Show Chwan,” says Ulf Claesson, CEO of Clinerion. “With this alliance, Clinerion can now offer clinical trial sponsors Taiwanese clinical expertise and facilities of the highest quality and professionalism, alongside a new patient population.”
Clinerion’s hospital coverage currently comprises hospital clusters with a catchment area of more than 30 million people, represented by around 400 million case files. Clinerion is continuing to pursue expansion of its hospital network across all continents.
About ASUS Life
ASUS Life is committed to the development and operation of intelligent hospital services. It focuses on medical big data and smart medical devices, with promoting the integration and innovation of medical care. It provides a comprehensive business deployment for government, medical institutions and health care service organizations with diversified and creative applications. ASUS Life is confident that medical data and smart medical devices will lead to innovation in health care services. By sharing, accumulating and analyzing, we will be able to continue to explore the new value of health information for the benefit of more people in need of care. With the leading technology development capabilities, global business platform, adequate cross-sectoral resources, trusted brand reputation and other advantages, ASUS Life is the lead in the transformation of healthcare industry. www.asus.life
Driving Diversity with the Integrated Research Model
October 16th 2024Ashley Moultrie, CCRP, senior director, DEI & community engagement, Javara discusses current trends and challenges with achieving greater diversity in clinical trials, how integrated research organizations are bringing care directly to patients, and more.
AI in Clinical Trials: A Long, But Promising Road Ahead
May 29th 2024Stephen Pyke, chief clinical data and digital officer, Parexel, discusses how AI can be used in clinical trials to streamline operational processes, the importance of collaboration and data sharing in advancing the use of technology, and more.
Carvykti Significantly Boosts Survival, MRD Negativity in Relapsed Multiple Myeloma
December 10th 2024Phase III CARTITUDE-4 trial shows Carvykti significantly improves minimal residual disease negativity rates, progression-free survival, and overall survival compared to standard therapies for patients with relapsed or refractory multiple myeloma, especially when used earlier in treatment.